Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

VanEck Vectors Biotech ETF (BBH)

131.44
Delayed Data
As of Jul 21
 +0.92 / +0.70%
Today’s Change
99.60
Today|||52-Week Range
131.52
+22.19%
Year-to-Date

Investment Objective

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVISä US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

3 ETFs Loaded with Positive ESP Stocks
Jul 14 / Zacks.com - Paid Partner Content
 

Performance

1 month+5.35% 3 years+11.57%
3 months+10.07% 5 years+22.02%
1 year+18.87% Since inception+26.63%
Data through 07/21/2017

Quote Details

Previous close$130.52
Open day’s range130.49 – 131.52
Net asset value (NAV)130.62 (07/20/2017)
Daily volume25,300
Average volume (3 months)35,776
Data as of 4:00pm ET, 07/21/2017

Peer Comparisonvs. Health ETFs

 BBHCategory
Performance 5-yr return+22.02%+17.39%
Expense Gross exp ratio0.40%1.33%
Risk 5 year sharpe ratio1.011.14
Net assets$677.8M$3.0B
Average market cap$35.6B$30.8B
Average P/E20.224.5
Dividend / Share--0.28%

Competitors

XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...
FHLC Fidelity® MSCI Health Care Index ETF

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
AMGN Amgen11.62%
CELG Celgene11.23%
GILD Gilead Sciences10.09%
AGN Allergan7.70%
BIIB Biogen5.73%
ALXN Alexion Pharmaceuticals Inc5.07%
REGN Regeneron Pharmaceuticals4.81%
INCY Incyte Corp4.52%
VRTX Vertex Pharmaceuticals Inc4.39%
Q Quintiles IMS Holdings Inc4.31%